Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Nubeqa

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

- PMLiVE

Five companies breach ABPI code

Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA

- PMLiVE

Bayer raises sales predictions for new pharma products

Expects Xarelto, Eylea, Stivarga, Xofigo and Adepas to make €7.5bn at peak

Bayer symbol

Bayer buys Chinese consumer care company

Acquires Dihon Pharmaceutical as Algeta takeover closes

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

Bayer symbol

Bayer drug cuts infusion burden in haemophilia A

Able to provide longer-term protection against bleeding episodes in late-stage trial

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

Bayer symbol

Bayer and Regeneron to develop second wet AMD therapy

Will collaborate on drug to be used in combination with Eylea

Bayer symbol

Bayer establishes research centre in Beijing

Pharma company will collaborate on cardiology, oncology, haematology and gynaecology projects

Bayer symbol

Bayer agrees $2.9bn deal for Algeta to get Xofigo control

Raises initial offer to buy Norweigan pharma company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links